The invention relates to novel ferroportin inhibitors of the general formula (I) pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, such as particularly iron overload states such as in particular thalassemia and hemochromatosis.
-
Page/Page column 127; 128
(2017/05/10)
INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE
The present invention is directed to compounds which inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and the farnesylation of the oncogene protein Ras.
-
(2008/06/13)
Synthesis of a new 1,4-dihydropyridine containing the imidazo[1,5-a]pyridine nucleus
-
Fos,Bosca,Mauleon,Carganico
p. 473 - 476
(2007/10/02)
Novel 1,4-dihydropyridine calcium antagonists. I. Synthesis and hypotensive activity of 4-(substituted pyridyl)-1,4-dihydropyridine derivatives